Extended Data Fig. 8: Dynamics of immune cell subsets in tumors and spleens derived from five syngeneic tumor models.
MC38, B16F10, CT26, EMT6 and LLC were collected and digested 1 week, 2 weeks and 3 weeks post implantations. Cell suspensions of tumors and spleens were stained and analyzed by flow cytometry (n = 6~8 mice). (a) Stacked bar graphs showing the proportion and absolute number of each immune cell subpopulation in different tumor models. (n = 6~8 mice). (b) Quantitation of CD25 expressions (MFI, measured by flow cytometry) in PD-1- versus PD-1+ CD8+TILs from different timepoints. Two-side paired t-test was used to calculate p-values. (c) Representative histograms showing mouse CD25 expression levels in CD8+TILs among five different tumor types (left). Correlational analysis between CD25+CD8+ frequency in intratumor CD8 and tumor growth inhibition of IL-2α-bias in five different syngeneic tumor models (right). (d) Correlational analysis of intratumor CD8+T, Treg or CD8/Treg ratio versus tumor growth inhibition (TGI%) of IL-2α-bias in five different syngeneic tumor models. (e) Correlational analysis of other intratumor immune subpopulations versus TGI% of IL-2α-bias in five different syngeneic tumor models (n = 6~8 mice). (f) Cell number/area and the percentage of CD8+T cell in tumor and adjacent tissue from CRC tissue microarray (n = 50 tumor samples) in Fig. 4g. Mean ± s.e.m. is presented, and p-values for linear regressions (C-E) were calculated by default using Graphpad Prism8 software, and p-values for dot plots were calculated by two-sided t-test (F).
